U2TH34 Stock Overview
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
United Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$56.21 |
| 52 Week High | US$57.62 |
| 52 Week Low | US$54.20 |
| Beta | 0.55 |
| 1 Month Change | 0% |
| 3 Month Change | 3.71% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -2.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| U2TH34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 0.4% |
| 1Y | n/a | -4.9% | 13.9% |
Return vs Industry: Insufficient data to determine how U2TH34 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how U2TH34 performed against the BR Market.
Price Volatility
| U2TH34 volatility | |
|---|---|
| U2TH34 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.8% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: U2TH34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine U2TH34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,168 | Martine Rothblatt | www.unither.com |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
United Therapeutics Corporation Fundamentals Summary
| U2TH34 fundamental statistics | |
|---|---|
| Market cap | R$57.41b |
| Earnings (TTM) | R$5.07b |
| Revenue (TTM) | R$11.98b |
11.3x
P/E Ratio4.8x
P/S RatioIs U2TH34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| U2TH34 income statement (TTM) | |
|---|---|
| Revenue | US$2.33b |
| Cost of Revenue | US$257.50m |
| Gross Profit | US$2.07b |
| Other Expenses | US$1.09b |
| Earnings | US$984.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 20.93 |
| Gross Margin | 88.94% |
| Net Profit Margin | 42.31% |
| Debt/Equity Ratio | 11.7% |
How did U2TH34 perform over the long term?
See historical performance and comparison